Secured $77.5M in combined debt and equity commitments to fund deSPAC and operations.
High-cost senior secured notes with aggressive monthly redemptions and first-priority liens.
Financing specifically tied to the business combination with Veraxa Biotech AG.
The 8-K filing reveals a high-stakes financial architecture designed to bridge the gap to a successful deSPAC. While the Lincoln Park agreement provides a theoretical $50 million safety net, the immediate reality is a demanding debt service schedule that could lead to rapid dilution if cash flows from operations remain insufficient. Investors must weigh the benefit of the available growth capital against the restrictive nature of the senior secured notes and the conditional nature of the equity line.